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Summary
Background Factors that might influence response to systemic treatment for
moderate-to-severe psoriasis are varied, and generally, are poorly understood,
aside from high bodyweight, suggesting that other unidentified factors may be
relevant in determining response to treatment. The impact of alcohol misuse on
treatment response has not been previously investigated.
Objectives To investigate whether alcohol misuse is associated with poor response
to treatment for psoriasis.
Methods This was a prospective cohort study in which response to systemic thera-
pies was assessed using the Psoriasis Area and Severity Index (PASI). The CAGE
(Cut down, Annoyed, Guilty, Eye opener) questionnaire was used to screen for
alcohol misuse. A multivariable factional polynomial linear regression model was
used to examine factors associated with change in PASI between baseline and
follow-up.
Results The cohort comprised 266 patients (biologic cohort, n = 134; conven-
tional systemic cohort, n = 132). For the entire cohort, the median (interquartile
range) PASI improved from 13 (100–183) at baseline to 3 (10–75) during
follow-up. A higher CAGE score [regression coefficient: 140, 95% confidence
interval (CI) 004–277]; obesity (184, 95% CI 048–320); and receiving a
conventional systemic rather than a biologic therapy (439, 95% CI 284–595)
were significantly associated with poor response to treatment; whereas a higher
baseline PASI (–083, 95% CI –092 to –074) was associated with a better
response to treatment.
Conclusions The poor response to therapy associated with alcohol misuse and obesity
found in people with psoriasis calls for lifestyle behaviour change interventions and
support as part of routine clinical care. Targeting interventions to prevent, detect
and manage alcohol misuse among people with psoriasis is needed to minimize
adverse health consequences and improve treatment response.
What is already known about this topic?
• Factors that might influence response to systemic treatment for moderate-to-severe
psoriasis are generally poorly understood, aside from high bodyweight, suggesting
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that other unidentified factors may be relevant in determining response to treat-
ment.
• The potential influence of alcohol misuse on response to treatment for psoriasis
has not been previously investigated.
What does this study add?
• After adjusting for important factors that could influence response to treatment
such as psychological distress and medication nonadherence, alcohol misuse was
found to be significantly associated with poor response to treatment.
• Identification of potentially modifiable factors associated with poor treatment
response emphasizes the need for lifestyle behaviour change support as part of rou-
tine clinical care.
• Effective interventions to detect and address high alcohol consumption should form
part of routine care for people with psoriasis.
Psoriasis is a chronic, immune-mediated inflammatory skin
condition. It is recognized by the World Health Organization
as a serious noncommunicable disease that requires effective
management.1 Psychological and social difficulties in combina-
tion with the physical discomfort associated with psoriasis
may contribute to psychological distress (anxiety and depres-
sion) and alcohol misuse.2–4
The treatment effectiveness of conventional systemic and
biologic therapies used in the management of moderate-to-
severe psoriasis is much lower in real-world clinical practice
than in clinical trials.5,6 Factors that might influence response
to treatment are varied, and generally, are poorly understood,
aside from high bodyweight, which has consistently been
associated with worse outcomes for most therapies.7–12 This
suggests that other unidentified factors may be relevant in
determining response.13 To date, previous research has
focused on demographic and clinical factors as predictors of
response to treatment in psoriasis.12 However, there are no
studies examining the role of alcohol misuse in predicting
response to treatment, taking into account other important
factors that could also influence treatment response such as
psychological distress and medication nonadherence.
The iMAP (Investigating Medication Adherence in Psoriasis)
is a multicentre study collecting biomedical and psychological
data from patients with psoriasis prescribed biologic or con-
ventional systemic therapies.14 All patients in iMAP are also
enrolled in the British Association of Dermatologists Biologics
and Immunomodulators Register (BADBIR), a longitudinal
pharmacovigilance register representing a ‘real-world’ cohort
of patients with psoriasis receiving biologic or conventional
systemic therapies.15,16 This presents an ideal resource to
assess the impact of alcohol misuse, alongside patient beha-
vioural and psychological factors on response to conventional
systemic and biologic therapies in routine clinical practice.
The objectives of this study were to: (i) assess real-world
levels of alcohol misuse, psychological distress and medication
nonadherence among patients with moderate-to-severe psoria-
sis, and (ii) investigate whether alcohol misuse is associated




Patients attending 35 dermatology centres across England were
recruited into iMAP between March 2013 and September
2016. Patients aged ≥ 18 years with a diagnosis of psoriasis
under the care of a dermatologist, prescribed a conventional
systemic and/or a biologic treatment and enrolled in BADBIR
were eligible for inclusion into iMAP.14
Data collection
The CAGE (Cut down, Annoyed, Guilty, Eye opener) ques-
tionnaire assessed self-perception of alcohol misuse. It consists
of four questions beginning with the stem ‘Have you ever’:
felt the need to cut down drinking; felt annoyed by criticism of
drinking; had guilty feelings about drinking; and taken a morn-
ing eye opener. The items are rated on a scale of 0–1, with a
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total score ranging from 0 to 4, with a score of ≥ 2 indicating
alcohol misuse.17,18
The Medication Adherence Report Scale (MARS) assessed the
frequency of nonadherent behaviours on a 5-point Likert scale
ranging from very often (1 point) to never (5 points), with
scores ranging from 8 to 40, with higher scores indicating
higher levels of adherent behaviour.19 Patients were classified
into an overall nonadherent category if they scored ≤ 38/4014
The Hospital Anxiety and Depression Scale (HADS) is a 14-
items scale that provides an assessment of symptoms of anxi-
ety (7 items) and depression (7 items). Items are rated on a
scale of 0–3, indicating the strength of agreement with that
item and are summed to create a HADS anxiety and depression
score, both ranging from 0 to 21, with a score of ≥ 8 indicat-
ing a possible ‘caseness’ of anxiety or depression.20,21 A score
ranging between 8–10, 11–14 and 15–21 indicate mild, mod-
erate and severe symptoms, respectively.22
Patients were instructed to independently and anonymously
complete an iMAP questionnaire that contained the MARS and the
HADS at baseline (upon recruitment) and every 6 months there-
after for up to 18 months. Patients’ demographic characteristics
(age, sex, height and weight); lifestyle information [smoking sta-
tus and alcohol misuse (CAGE)]; details of type and severity of
psoriasis [Psoriasis Area and Severity Index (PASI)] and year of
onset; standardized measures of health status using self-reported
outcome measures [Dermatology Life Quality Index (DLQI)];
detailed information about the patients’ current and previous
treatments for psoriasis (any change in therapy, concomitant use
of systemic therapies, gaps in treatment, start and stop dates, and
reasons for discontinuation); and the patients’ comorbidities were
extracted from BADBIR (with written informed patient consent)
at times corresponding to the dates when the patients completed
the iMAP questionnaires. Data were extracted from the October
2018 database build.
Study population
Patients were eligible for inclusion in this analysis if they had
at least one PASI measurement recorded before and after com-
pleting at least one iMAP questionnaire. The PASI recorded
closest to the date of completing the iMAP questionnaire were
identified and referred to as either ‘baseline’ (recorded prior
to completing the questionnaire) or ‘follow-up’ PASI
(recorded after completing the questionnaire). The majority of
the patients had only one iMAP questionnaire, although a few
had multiple questionnaires completed between the time the
baseline and follow-up PASIs were recorded (File S1 and Fig-
ure S1; see Supporting Information). Patients were excluded
from the analysis if the baseline PASI was measured
> 12 months prior to or > 1 month after the start of therapy;
and/or if their follow-up PASI was measured > 24 months
after the start of their treatment. Patients were assigned to
either the biologic or conventional systemic cohort based on
the therapy they were receiving at the time of completing
their first iMAP questionnaire, and patients were recorded as
either biologic naive or non-naive.
Statistical analysis
Multivariable linear regression model, where fractional poly-
nomials were used to model nonlinear relationships between
the covariates and the outcome, was conducted to investigate
factors associated with the change in PASI between baseline
and follow-up. An a priori list of covariates was determined to
address potential predictors of response. Alcohol misuse
(CAGE), medication nonadherence and psychological distress
recorded at times corresponding to the dates when the
patients completed the iMAP questionnaires were included in
the model. In the few patients with more than one valid mea-
surement of the CAGE (19 patients, 7%), patients’ medication
nonadherence status (28 patients, 11%) and psychological dis-
tress (28 patients, 11%) during the study period, an average
was taken. An interaction between overall medication nonad-
herence status and the cohort the patients were assigned to
was also included in the model.
Other potential confounders included in the model were
body mass index (dated around the start date of the therapy)
which was categorized into a binary obese/nonobese variable.
The patients’ age and disease duration were calculated from
the patients’ date of birth and year of disease onset recorded
at the time of registration into BADBIR and the start date of
their therapy, respectively. Participants’ baseline DLQI were
identified if they were dated within 12 months prior to and
1 month after the start of treatment to be consistent with how
baseline PASI were identified. The median [interquartile range
(IQR)] time period between the baseline DLQI measurement
and start of therapy was –4 days (–37 to 0 days).
Inflammatory arthritis and other comorbidities as well as
the patients’ smoking status were collected at the time of reg-
istration into BADBIR. Concomitant use of methotrexate,
ciclosporin and/or other conventional systemic therapies was
analysed as a binary variable (ever exposed/never exposed)
throughout the study. A sensitivity analysis was conducted in
which an interaction between alcohol misuse and obesity was
also included in the model.
To account for missing data (Table S1, see Supporting
Information), we generated 50 imputed datasets. In each data-
set, missing values were replaced by values randomly selected
from the expected distribution of that variable conditional on
the measured or imputed values of all other variables for that
individual. This approach enables all participants to be
included in the analysis, avoiding the selection bias that would
be likely if only participants with complete data were included
for analysis.23 The multivariable linear regression assumptions
were assessed by scatterplots and statistical testing. Analyses
were performed using Stata version 150 (Stata Corp, College
Station, TX).
Ethical approval
Ethical approval for BADBIR and iMAP were obtained from
the NHS research Ethics Committee North West England (ref-
erences 07/MRE08/9 and 12/NW/0619, respectively) in
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March 2007 and December 2012, respectively, and from
research ethics committees local to each recruiting site. All
participants gave written informed patient consent for their
participation in the registry prior to data collection.
Results
In total, 266 patients with psoriasis (biologic cohort, n = 134;
conventional systemic cohort, n = 132) were included in our
analyses (Figure 1); they were followed-up for a median
(IQR) of 7 (6–10) months. The mean (SD) age of patients
and disease duration were 482 (131) and 221 (145) years,
respectively, and 451% of participants were women.
At baseline, the median PASI was 13 (IQR 10–183) and
the mean DLQI was 162 (SD 85). Overall, 195% of partici-
pants reported having inflammatory arthritis, and 673%
reported having ≥1 comorbidities other than inflammatory
arthritis. Patients’ demographic and disease characteristics are
summarized in Table 1.
The mean CAGE score was 03 (SD 08), with 56% of
patients scoring ≥ 2 indicating alcohol misuse (Table 1). The
mean (SD) HADS anxiety and depression scores were 69 (45)
Figure 1 Flow chart showing selection of study participants. aThe Psoriasis Area and Severity Index (PASI) recorded closest to the date of
completing the iMAP (Investigating Medication Adherence in Psoriasis) questionnaire were identified and referred to as either baseline PASI
(recorded prior to completing the questionnaire) or follow-up PASI (recorded after completing the questionnaire).
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(504%, n = 134)
Conventional cohortb
(496%, n = 132)
Age (years), mean (SD) 482 (131) 481 (135) 484 (128)
Female 120 (451) 52 (388) 68 (515)
BMI category, kg/m2
Nonobese (BMI < 30) 145 (545) 63 (470) 82 (621)
Obese (BMI ≥ 30) 121 (455) 71 (530) 50 (379)
Smoking status
Never smoked 86 (323) 47 (351) 39 (295)
Ex-smoker 98 (368) 52 (388) 46 (348)
Current smoker 82 (308) 35 (261) 47 (356)
Alcohol use
CAGE,c mean (SD) 03 (08) 03 (07) 03 (08)
Alcohol misuse 15 (56) 7 (52) 8 (61)
Inflammatory arthritis/other comorbidities
Inflammatory arthritis 52 (195) 30 (224) 22 (167)
No comorbiditiesd 87 (327) 39 (291) 48 (364)
1–2 comorbiditiesd 122 (459) 63 (470) 59 (447)
3–4 comorbiditiesd 50 (188) 28 (209) 22 (167)
≥ 5 comorbiditiesd 7 (26) 4 (30) 3 (23)
Disease
Disease duration (years), mean (SD) 221 (145) 236 (140) 205 (149)
Age of onset (years), mean (SD) 262 (159) 244 (152) 279 (165)
PASI at baseline, median (IQR) 131 (10–183) 134 (92–194) 128 (102–171)
DLQI at baseline, mean (SD) 162 (85) 158 (94) 165 (76)
Unstable psoriasis 37 (139) 17 (127) 20 (152)
Psychological distress (HADS)
Anxiety score,e mean (SD) 69 (45) 67 (43) 70 (46)
Anxiety severityf
No anxiety 158 (594) 80 (597) 78 (593)
Mild anxiety 53 (199) 29 (216) 24 (185)
Moderate anxiety 39 (147) 19 (142) 20 (146)
Severe anxiety 16 (60) 6 (45) 10 (76)
Depression score,e mean (SD) 53 (41) 53 (41) 53 (42)
Depression severityf
No depression 193 (726) 99 (739) 94 (709)
Mild depression 41 (154) 20 (149) 21 (161)
Moderate depression 27 (102) 13 (97) 14 (107)
Severe depression 5 (19) 2 (15) 3 (23)
Medication nonadherence
Overall nonadherent 44 (165) 8 (60) 36 (276)
Medication history
Biologic naive 238 (895) 106 (791) 132 (1000)
Concomitant systemic therapyg 28 (105) 17 (127) 11 (82)
Stopped therapyh 42 (158) 16 (119) 26 (194)
Results are n (%) unless otherwise indicated. BMI, body mass index; CAGE, Cut down, Annoyed, Guilty and Eye opener; DLQI, Dermatology
Life Quality Index; HADS, Hospital Anxiety and Depression Scale; IQR, Interquartile range; PASI, Psoriasis Area and Severity Index. aIncludes
adalimumab (69, 515%); etanercept (17, 127%); ustekinumab (45, 336%); and other biologic therapies (infliximab, golimumab, secuk-
inumab) (3, 23%). bIncludes acitretin (33, 250%); ciclosporin (32, 242%); Fumaric acid esters (7, 53%); methotrexate (60, 455%). cThe
possible score range for CAGE is 0–4. dIncludes any of (excluding inflammatory arthritis) hypertension, angina, ischaemic heart disease,
stroke, epilepsy, asthma, chronic obstructive pulmonary disease, peptic ulcer, renal disease, hepatic disease, tuberculosis, demyelinating dis-
ease, diabetes, impaired glucose tolerance, depression, nonskin cancer, immunodeficiency syndrome, thyroid disease, other. eThe possible
score range for HADS anxiety and HADS depression is 0–21. fThe possible score range for HADS anxiety and HADS depression severity is
mild, 8–10; moderate, 11–14; severe, 15–21. gIncludes any of acitretin, fumaric acid esters, ciclosporin, methotrexate and mycophenolate
mofetil. hPatients stopped therapy received at the time of completing the iMAP (iMAP, Investigating Medication Adherence in Psoriasis) ques-
tionnaire during the study period.
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and 53 (41), with 406% and 274% of patients scoring ≥ 8
indicating a possible caseness of anxiety and depression, respec-
tively (Table 1). A notable proportion of the study cohort were
classified as nonadherent to medication (165%; Table 1), with
a significantly higher proportion of patients using conventional
systemic therapies classified as nonadherent (276%) compared
with those using biologic therapies (60%).
Table 2 presents results from the multivariable linear regres-
sion analysis examining factors that affect the change in PASI
between baseline and follow-up. Having a higher CAGE score
was significantly associated with poor response to treatment as
measured by change in PASI [for every 1-point increase in the
CAGE score; regression coefficient 140, 95% confidence inter-
val (CI) 004– 277. Thus, a maximum change in CAGE score
from 0 to 4 would be associated with a change in PASI of
560, 95% CI 016–1108].
Of the demographic factors, with each 10-year increase in a
patient’s age there was significantly better response to treat-
ment (–063, 95% CI –122 to –005). Having a higher base-
line PASI (for every 1-point increase in the baseline PASI, –
Table 2 Multivariable linear regression of potential factors associated with changes in Psoriasis Area Severity Index (PASI) between baseline and
follow-up
Variable b coefficient (95% CIs) P-value
Demographics
Agea –063 (–122 to –005) 0035
Female –005 (–137 to 127) 0940
Obesity statusb
Obese (BMI 30 kg/m2) 184 (048 to 320) 0008
Smoking statusc
Ex-smoker –121 (–275 to 033) 0123
Current smoker –120 (–283 to 044) 0151
Comorbiditiesd
Inflammatory arthritis –028 (–196 to 140) 0745
1–2 comorbidities –040 (–188 to 108) 0595
3–4 comorbidities 030 (–175 to 235) 0774
≥ 5 comorbidities –131 (–562 to 299) 0549
Disease
Disease durationa 028 (–021 to 077) 0258
Baseline PASI –083 (–092 to –074) <0001
Baseline DLQI –006 (–017 to 006) 0339
CAGE 140 (004 to 277) 0044
Psychological distress (HADS)
Anxiety –003 (–024 to 017) 074
Depression 018 (–004 to 039) 0110
Overall nonadherent 265 (–549 to 1079) 0522
Treatment
Conventional systemic cohorte 439 (284 to 595) <0001
Biologic naivef –176 (–419 to 068) 0156
Concomitantly using conventional systemic therapyg 178 (–036 to 391) 0102
Stopped therapyh 418 (238 to 597) <0001
Time gap between start of therapy and time the baseline PASI was measured 021 (–022 to 065) 0334
Time gap between start of therapy and time the follow-up PASI was measured –012 (–028 to 004) 0138
Nonadherence: conventional systemic cohorti –220 (–668 to 229) 0336
BMI, body mass index; CAGE, Cut down, Annoyed, Guilty and Eye opener; CI, confidence interval; DLQI, Dermatology Life Quality Index;
HADS, Hospital Anxiety and Depression Scale. Results in bold indicates P ≤ 005. Fractional polynomials were used to determine if any non-
linear association between the covariates and the outcome provided a better fit than a simple linear association, but none did. aTo evaluate
regression coefficients for every 10-year increase in age and disease duration at enrolment into the British Association of Dermatologists Bio-
logics and Immunomodulators Register, baseline continuous variables of age and disease duration were transformed to age and disease dura-
tion divided by 10. At follow-up, older age at enrolment (by 10 years) was associated with greater improvement in PASI values. bReference
category: nonobese (BMI < 30 kg/m2). cReference category: never smoked. dReference category: no comorbidities (excluding inflammatory
arthritis); includes any of hypertension, angina, ischaemic heart disease, stroke, epilepsy, asthma, chronic obstructive pulmonary disease,
peptic ulcer, renal disease, hepatic disease, tuberculosis, demyelinating disease, diabetes, impaired glucose tolerance, depression, nonskin can-
cer, immunodeficiency syndrome, thyroid disease, other. eReference category: biologic cohort. fReference category: biologic non-naive. gIn-
cludes any of acitretin, fumaric acid esters, ciclosporin, methotrexate and mycophenolate mofetil. Included as a binary variable (ever
exposed/never exposed). Reference category: never exposed. hPatients stopped therapy received at the time of completing the iMAP (Investi-
gating Medication Adherence in Psoriasis) questionnaire during the study period. Reference category: continuously used therapy throughout
the study period. iAn interaction term between cohort and overall nonadherence status.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
6 Alcohol misuse and response to treatment for psoriasis, I.Y.K. Iskandar et al.
083, 95% CI –092 to –074) was also significantly associated
with a better response to treatment. In contrast, being obese
(184, 95% CI 048–320), receiving a conventional systemic
therapy rather than a biologic therapy (439, 95% CI 284–
595), and stopping the therapy during the follow-up (418,
95% CI 238–597) were significantly associated with poor
response to treatment. No significant interaction was found
between medication nonadherence and treatment cohort
(P = 0336, Table 2) and also between alcohol misuse (CAGE)
and obesity (P = 0930, Table S2, see Supporting Informa-
tion).
Discussion
In this real-world cohort of patients with psoriasis, alcohol
misuse, obesity and receiving a conventional systemic therapy
were significantly associated with poor response to treatment
as measured by change in PASI between baseline and follow-
up. To our knowledge this is the first study to investigate
alcohol misuse in a real-world cohort of patients with psoria-
sis, and explore how it affects response to treatment.
Consistent with other studies, we found that obesity was
also associated with poor response to systemic therapies.7–9
Obesity has also been found to be associated with poor
response to therapies in rheumatoid arthritis24,25 and anky-
losing spondylitis.26 Our findings are also in line with those
reported by Gelfand et al.,5 who found biologic therapies to
be more effective than conventional systemic therapies. How-
ever, by comparison, our study has an important strength:
we accounted for important clinical and social factors includ-
ing smoking status, alcohol misuse, the presence of comor-
bidities and medication nonadherence. Although overall
nonadherence did not significantly predict response to ther-
apy (P = 0522), the results suggest that it was associated
with poor response for those exposed to conventional sys-
temic therapies (265, 95% CI –549 to 1079). Clinicians
should therefore explore patients’ adherence, especially in
those who are poor responders to therapy, and provide addi-
tional support to improve adherence to treatment regimens.27
Future studies investigating predictors of response to therapy
should ideally include a measure of adherence to reduce
potential confounding.
To our knowledge, no previous study has assessed the asso-
ciation of alcohol misuse with poor response to therapies.7
Our results demonstrate that alcohol misuse is associated with
poor response to treatment. We would be interested to see
whether our findings can be replicated independently. The
implications of our findings are important. The economic,
social and health consequences of alcohol misuse are consider-
able. Excessive alcohol may worsen the disease, has implica-
tions for treatment and increases the risk of dying in people
with psoriasis – this is on average 3 years younger compared
with peers of the same age and sex in the general popula-
tion.28,29
One of the key strengths of this study is the real-world
prospective cohort study design thereby ensuring that patients
are representative of those receiving treatment in routine clini-
cal practice. Furthermore, the participation of multiple derma-
tology centres (n = 35) across England ensures the external
validity of the results. We also performed multiple imputation
to account for missing data thus minimizing the bias that
could have been introduced by only considering a complete
case analysis.
Limitations include the use of self-reported tools for alcohol
misuse, medication nonadherence and psychological distress,
which can be criticized for being influenced by poor patient
recall or reporting bias and so may underestimate alcohol mis-
use or overestimate adherence and psychological distress. The
CAGE questionnaire can also be criticized for identifying
mostly severe forms of harmful alcohol misuse and depen-
dence, and so can fail to adequately identify those with haz-
ardous use of alcohol. Nevertheless, it is reported that the
CAGE has a sensitivity of 93% and a specificity of 76% for the
identification of excessive drinking and the use of appropriate
theoretical frameworks and validated data-collection tools are
major strengths.30,31
An inherent limitation in any observational study is lack
of randomization, which may introduce confounding bias,
and although this is partially negated by adjustment for
clinically relevant covariates, the presence of other unmea-
sured confounders, such as the intention behind concomi-
tant medication, cannot be determined. One particular
challenge we faced is that some of the patients’ demo-
graphic characteristics were recorded only at the time of
registration with BADBIR. This included data on smoking
status and comorbidities. It is possible that some patients
may have developed new comorbidities or changed smoking
status during the study period. Furthermore, the influence
of treatment dose escalation on the PASI response was not
assessed. However, we have shown previously that patients
in BADBIR routinely receive the recommended dosing regi-
men but that concomitant treatment with other systemic
therapies occurs commonly.32
Clinicians should be aware of the considerable psychological
distress and psychosocial challenges that are faced by patients
with psoriasis, which can lead to chronic alcohol misuse and
dependence as coping mechanisms.29 Our findings highlight
that at least 40% of our study cohort reported having psycho-
logical distress and that alcohol misuse has a negative effect
on response to treatment. Psychological and educational inter-
ventions for newly diagnosed patients with psoriasis have
been developed to minimize distress and to alert patients to
the negative impact of alcohol on psoriasis outcomes (for
example Chisholm et al.33 and Nelson et al.34). For those with
established disease, the recognition by clinicians of the risks
associated with the dual stigma of psoriasis and alcohol misuse
on response to treatment is important. Discussions about alco-
hol use, especially high use, are challenging for both clinicians
and patients through fear of stigmatization, and as a result, are
frequently avoided in consultations.35 Patients may also be
unaware of the extent to which they are using alcohol as a
coping mechanism. Nevertheless, provision of skilled
© 2021 The Authors. British Journal of Dermatology
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screening and brief interventions by healthcare teams can
enable patients to achieve reduction or abstinence, reduce
health harms and improve prognosis without increasing
stigma.36–38
Our findings also indicate that clinicians need to be aware
of, and address, the possibility of medication nonadherence.
The behaviour of more than 15% of patients in this study
were classified as being nonadherent. Patients’ beliefs about
their medication, including concerns about the potential for
adverse events, are key drivers of nonadherence. Concerns
about unwanted treatment effects are common in patients
with psoriasis, including those who adhere to treatments,39
and so provision of accessible patient-centred materials (using
traditional written or e-health delivery formats) that address
these issues may allay some worry in a time efficient way.
This can be further supported by all those involved in provi-
sion of treatment, including medical, nursing and pharmacy
staff, all of whom have a role in shaping patients’ treatment
beliefs. People are more likely to forget to use their medica-
tion if they have weak medication-taking habits or routines.14
Again, very brief messages either delivered directly from rele-
vant clinical staff, or via traditional or electronic media, may
enable patients to recognize that habit formation requires an
initial period of active engagement in change and could opti-
mize treatment outcomes.27
In conclusion, this study provides evidence that alcohol
misuse and obesity are associated with poor response to treat-
ment in patients receiving systemic therapies. These are modi-
fiable factors and confirm the important role that clinical
teams can play in supporting lifestyle behaviour change in
people with psoriasis. Interventions to prevent or address alco-
hol misuse and weight gain are important parts of psoriasis
health management. Patients may need additional support to
recognize the relevance of these lifestyle factors to their skin
health;34,40 and this study highlights how these factors detri-
mentally affect psoriasis treatment effectiveness. Routine
screening and identification, using simple screening tools, can
be used to detect early signs of hazardous, harmful and
dependent alcohol consumption, and can be implemented in
healthcare settings to detect alcohol misuse among people
with psoriasis.38
Acknowledgments
The authors acknowledge the contribution of the Psoriasis
Stratification to Optimise Relevant Therapy (PSORT) partners,
and the PSORT Executive Committee (in alphabetical order):
Jonathan Barker, Michael Barnes, David Burden, Paola DiMe-
glio, Richard Emsley, Christopher Griffiths (Chair), Katherine
Payne, Nick Reynolds, Catherine Smith, Deborah Stocken and
Richard Warren.
The British Association of Dermatologists Biologic and
Immunomodulators Register (BADBIR) acknowledges the sup-
port of the National Institute for Health Research (NIHR)
through the clinical research networks and its contribution in
facilitating recruitment into the registry. The views and
opinions expressed therein are those of the authors and do
not necessarily reflect those of the BADBIR, NIHR,
the National Health Service or the Department of Health.
The authors are also grateful to the members of the Data
Monitoring Committee: Robert Chalmers, Carsten Flohr
(Chair), Richard Weller, and David Prieto-Merino and the
BADBIR Steering Committee (in alphabetical order): Jonathan
Barker, Marilyn Benham (CEO of BAD), David Burden (Chair),
Ian Evans, Christopher Griffiths, Sagair Hussain, Brian Kirby,
Linda Lawson, Kayleigh Mason, Kathleen McElhone, Ruth
Murphy, Anthony Ormerod, Caroline Owen, Nick Reynolds,
Catherine Smith and Richard Warren.
Christopher Griffiths is an NIHR Emeritus Senior Investiga-
tor. We acknowledge the enthusiastic collaboration of all of
the dermatologists and specialist nurses in the UK and the
Republic of Ireland who provided the data. The principal
investigators at the BADBIR participating sites are listed on the
following website: http://www.badbir.org.
Finally, we are very grateful to all individuals with psoria-
sis who took part in this study.
References
1 World Health Organization. Global Report on Psoriasis. Geneva: World
Health Organization, 2016.
2 Kimball AB, Jacobson C, Weiss S et al. The psychosocial burden of
psoriasis. Am J Clin Dermatol 2005; 6:383–92.
3 Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on
quality of life: results of a 1998 National Psoriasis Foundation
patient-membership survey. Arch Dermatol 2001; 137:280–4.
4 Hayes J, Koo J. Psoriasis: depression, anxiety, smoking, and drink-
ing habits. Dermatol Ther 2010; 23:174–80.
5 Gelfand JM, Wan J, Callis Duffin K et al. Comparative effectiveness
of commonly used systemic treatments or phototherapy for mod-
erate to severe plaque psoriasis in the clinical practice setting. Arch
Dermatol 2012; 148:487–94.
6 Iskandar IYK, Ashcroft DM, Warren RB et al. Comparative effective-
ness of biological therapies on improvements in quality of life in
patients with psoriasis. Br J Dermatol 2017; 177:1410–21.
7 Edson-Heredia E, Sterling KL, Alatorre CI et al. Heterogeneity of
response to biologic treatment: perspective for psoriasis. J Invest
Dermatol 2014; 134:18–23.
8 Di Lernia V, Ricci C, Lallas A et al. Clinical predictors of non-
response to any tumor necrosis factor (TNF) blockers: a retrospec-
tive study. J Dermatolog Treat 2014; 25:73–4.
9 Garcıa-Doval I, Perez-Zafrilla B, Ferrandiz C et al. Development
of clinical prediction models for good or bad response to classic
systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based
on the BIOBADADERM cohort. J Dermatolog Treat 2016; 27:
203–9.
10 Umezawa Y, Saeki H, Nakagawa H. Some clinical factors affecting
quality of the response to ustekinumab for psoriasis. J Dermatol
2014; 41:690–6.
11 Zweegers J, Roosenboom B, van de Kerkhof PC et al. Frequency
and predictors of a high clinical response in patients with psoriasis
on biological therapy in daily practice: results from the prospec-
tive, multicenter BioCAPTURE cohort. Br J Dermatol 2017;
176:786–93.
12 Warren RB, Marsden A, Tomenson B et al. Identifying demo-
graphic, social and clinical predictors of biologic therapy
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
8 Alcohol misuse and response to treatment for psoriasis, I.Y.K. Iskandar et al.
effectiveness in psoriasis: a multicentre longitudinal cohort study.
Br J Dermatol 2019; 180:1069–76.
13 Foulkes AC, Watson DS, Carr DF et al. A framework for multi-
omic prediction of treatment response to biologic therapy for pso-
riasis. J Invest Dermatol 2019; 139:100–7.
14 Thorneloe RJ, Griffiths CEM, Emsley R et al. Intentional and unin-
tentional medication mon-adherence in psoriasis: the role of
patients’ medication beliefs and habit strength. J Invest Dermatol
2018; 138:785–94.
15 Burden AD, Warren RB, Kleyn CE et al. The British Association of
Dermatologists’ Biologic Interventions Register (BADBIR): design,
methodology and objectives. Br J Dermatol 2012; 166:545–54.
16 Iskandar IYK, Ashcroft DM, Warren RB et al. Demographics and
disease characteristics of patients with psoriasis enrolled in the Bri-
tish Association of Dermatologists Biologic Interventions Register.
Br J Dermatol 2015; 173:510–8.
17 Ewing JA. Detecting alcoholism. The CAGE questionnaire. JAMA
1984; 252:1905–7.
18 Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation
of a new alcoholism screening instrument. Am J Psychiatry 1974;
131:1121–3.
19 Horne R, Weinman J. Self-regulation and self-management in
asthma: exploring the role of illness perceptions and treatment
beliefs in explaining non-adherence to preventer medication. Psy-
chol Health 2002; 17:17–32.
20 Zigmond AS, Snaith RP. The hospital anxiety and depression scale.
Acta Psychiatr Scand 1983; 67:361–70.
21 Bjelland I, Dahl AA, Haug TT et al. The validity of the Hospital
Anxiety and Depression Scale. An updated literature review. J Psy-
chosom Res 2002; 52:69–77.
22 Stern AF. The Hospital Anxiety and Depression Scale. Occup Med
2014; 64:393–4.
23 Bodner TE. What improves with increased missing data imputa-
tions? Struct Equ Modeling 2008; 15:651–75.
24 McWilliams DF, Walsh DA. Factors predicting pain and early dis-
continuation of tumour necrosis factor-a-inhibitors in people with
rheumatoid arthritis: results from the British society for rheuma-
tology biologics register. BMC Musculoskelet Disord 2016; 17:337.
25 Kleinert S, Tony HP, Krause A et al. Impact of patient and disease
characteristics on therapeutic success during adalimumab treatment
of patients with rheumatoid arthritis: data from a German nonin-
terventional observational study. Rheumatol Int 2012; 32:2759–67.
26 Ottaviani S, Allanore Y, Tubach F et al. Body mass index influences
the response to infliximab in ankylosing spondylitis. Arthritis Res
Ther 2012; 14:R115.
27 National Institute for Health and Care Excellence. Medicines Adherence:
Involving Patients in Decisions about Prescribed Medicines and Supporting Adher-
ence. NICE, 2009. Available at: https://www.nice.org.uk/Guida
nce/CG76 (last accessed 29 June 2019).
28 McAleer MA, Mason DL, Cunningham S et al. Alcohol misuse in
patients with psoriasis: identification and relationship to disease
severity and psychological distress. Br J Dermatol 2011; 164:1256–61.
29 Parisi R, Webb RT, Carr MJ et al. Alcohol-related mortality in
patients with psoriasis: a population-based cohort study. JAMA Der-
matol 2017; 153:1256–62.
30 Bernadt MW, Mumford J, Taylor C et al. Comparison of question-
naire and laboratory tests in the detection of excessive drinking
and alcoholism. Lancet 1982; 1:325–8.
31 Williams N. The CAGE questionnaire. Occup Med 2014; 64:473–4.
32 Iskandar IYK, Ashcroft DM, Warren RB et al. Patterns of biologic
therapy use in the management of psoriasis: cohort study from
the British Association of Dermatologists Biologic Interventions
Register (BADBIR). Br J Dermatol 2017; 176:1297–307.
33 Chisholm A, Nelson PA, Pearce CJ et al. Motivational interviewing-
based training enhances clinicians’ skills and knowledge in psoria-
sis: findings from the Pso Well study. Br J Dermatol 2017;
176:677–86.
34 Nelson PA, Kane K, Pearce CJ et al. ’New to me’: changing patient
understanding of psoriasis and identifying mechanisms of change.
The Pso Well patient materials mixed-methods feasibility study.
Br J Dermatol 2017; 177:758–70.
35 Kirby B, Richards HL, Mason DL et al. Alcohol consumption and
psychological distress in patients with psoriasis. Br J Dermatol 2008;
158:138–40.
36 The British Society of Gastroenterology and Bolton NHS Founda-
tion Trust. Alcohol Care Teams: Reducing Acute Hospital Admissions and
Improving Quality of Care. London and Bolton: The British Society of
Gastroenterology and Bolton NHS Foundation Trust, 2016.
37 Moriarty KJ, Cassidy P, Dalton D et al. Alcohol-Related Disease. Meeting
the challenge of improved quality of care and better use of resources. London:
BSG, 2018. Available at: https://www.bsg.org.uk/resource/alc
ohol-related-disease-meeting-the-challenge-of-improved-quality-
of-care-and-better-use-of-resources.html (last accessed 29 June
2019)
38 Carvalho AF, Heilig M, Perez A et al. Alcohol use disorders. Lancet
2019; 394:781–92.
39 Thorneloe RJ, Bundy C, Griffiths CE et al. Nonadherence to psoria-
sis medication as an outcome of limited coping resources and
conflicting goals: findings from a qualitative interview study with
people with psoriasis. Br J Dermatol 2017; 176:667–76.
40 Nelson PA, Kane K, Chisholm A et al. ’I should have taken that fur-
ther’ - missed opportunities during cardiovascular risk assessment
in patients with psoriasis in UK primary care settings: a mixed-
methods study. Health Expect 2016; 19:1121–37.
Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
File S1. Methods.
Table S1. Missing data.
Table S2. Multivariable fractional polynomial linear regres-
sion of potential factors associated with changes in Psoriasis
Area Severity Index (PASI) between baseline and follow-up.
Figure S1. iMAP (Investigating Medication Adherence in
Psoriasis) questionnaire completion in relation to time of Pso-
riasis Area Severity Index (PASI) measurement.
© 2021 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2021)
Alcohol misuse and response to treatment for psoriasis, I.Y.K. Iskandar et al. 9
